<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0263353" disease_type="Disease or Syndrome" abbrv="">Prurigo nodularis</z:e> is a <z:hpo ids='HP_0011010'>chronic</z:hpo>, relapsing <z:e sem="disease" ids="C0027822" disease_type="Disease or Syndrome" abbrv="">neurodermatitis</z:e> that is often resistant to standard therapies with topical <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and oral <z:chebi fb="5" ids="37956">antihistamines</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Thalidomide, while efficacious in treating recalcitrant cases of <z:e sem="disease" ids="C0263353" disease_type="Disease or Syndrome" abbrv="">prurigo nodularis</z:e>, causes significant toxicity </plain></SENT>
<SENT sid="2" pm="."><plain>Thalidomide-induced <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> frequently results in drug discontinuation </plain></SENT>
<SENT sid="3" pm="."><plain>Lenalidomide (Revlimid; Celgene Corporation, Summit, NJ) is a derivative of thalidomide with less neurotoxicity approved for the treatment of <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> that has not been widely studied in dermatologic disorders </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we report a case of refractory <z:e sem="disease" ids="C0263353" disease_type="Disease or Syndrome" abbrv="">prurigo nodularis</z:e> effectively treated with lenalidomide </plain></SENT>
<SENT sid="5" pm="."><plain>Given its favorable side-effect profile, lenalidomide may offer a superior alternative to thalidomide in the treatment of this condition </plain></SENT>
</text></document>